Second quarter revenue for Sarepta Therapeutics Inc. (Nasdaq: SRPT) exceeded expectations by a wide margin prompting the biopharmaceutical to lift its full year forecast. The stock price leaped $6.85 to close at $40.93.
Sarepta Therapeutics tops estimates
July 20, 2017 at 17:15 PM EDT